### 🔴 Sanofi CEO Ousted — Belén Garijo Incoming (Feb 12)
Sanofi's board removed CEO **Paul Hudson** effective Feb 17, citing stalled turnaround, weak vaccine sales, and R&D setbacks. **Belén Garijo** (ex-Merck KGaA CEO) takes over by late April; **Olivier Charmeil** serves as interim. Hudson's six-year ten
- **Patient Finder Impact:** Major leadership change at a top target. All Sanofi outreach contacts should be flagged for potential reorg. Paul Hudson was a known decision maker — he's now OUT. New CEO will reshape commercial priorities. Pause any pen
- Sources: [BiopharmaDive](https://www.biopharmadive.com/news/sanofi-ceo-paul-hudson-belen-garijo/812061/), [BioSpace](https://www.biospace.com/press-releases/press-release-belen-garijo-to-become-chief-executive-officer-of-sanofi)
### 🔴 Eli Lilly Acquires Orna Therapeutics for $2.4B — In Vivo CAR-T Play (Feb 9)
Lilly acquiring Orna Therapeutics (circular RNA / in vivo CAR-T platform) for up to $2.4B. Lead candidate ORN-252 targets CD19 for autoimmune diseases. IND filing expected; trials in 2026. This follows Lilly's $1.12B Seamless Therapeutics deal and $1
- **Patient Finder Impact:** Lilly expanding rapidly into autoimmune/rare disease via cell therapy. New undiagnosed patient populations may emerge. Monitor for patient identification needs around autoimmune indications.
- Sources: [Pharma-Technology](https://www.pharmaceutical-technology.com/news/eli-lilly-acquires-orna-therapeutics-in-vivo-car-t-2-4bn/), [STAT](https://www.statnews.com/2026/02/09/eli-lilly-buys-orna-therapeutics-in-vivo-car-t/)